Quick Summary
Additional Context
Desktop 3D printer manufacturer UltiMaker and Singaporean MedTech startup Bioactivx have signed a memorandum of understanding (MoU) to jointly develop a deployable, on-demand 3D printing solution for regenerative wound care.
The announcement coincides with two milestones Bioactivx reached. The more significant of the two is Health Sciences Authority (HSA) approval for Bioactivx’s flagship product, the Bioactiv Matrix, a fully synthetic, animal-free artificial skin substitute designed to treat severe burns, cuts, and abrasions.
Singapore’s HSA sits at World Health Organization (WHO) Maturity Level 4 for medical device regulation, indicating extremely high standards for medical device approvals, and Bioactivx has ongoing regulatory submissions in the United States, the European Union, Aust